TEM Stock Forecast & Price Target

Tempus AI is favored because its FDA-cleared ECG-PH product deepens the cardiovascular portfolio, broadens the addressable cardiology market, and reinforces the scalability of its AI-enabled diagnostics platform. The pending Personalis acquisition adds a differentiated MRD asset, while Merck and Moderna’s positive INTerpath-001 readout validates individualized neoantigen therapy and could lift sequencing demand, biopharma activity, and platform value. Fundamentally, the company also has visible monetization catalysts from xT CDx’s FDA approval, expected ASP improvement of about $200 per test, and management’s estimate of roughly $400M of incremental revenue in 2028, supporting a constructive long-term outlook.

Tempus AI is challenged by a demanding valuation framework and a risk profile that leaves little room for execution missteps, especially as its next-12-month sales per share of $9.87 must support a premium EV/Revenue multiple while net debt stands at $3.00 per share. The company also faces meaningful downside from competition, regulatory delays, technological obsolescence, and an inability to sustain profitability, while dependence on biopharmaceutical partnerships and new product approvals adds further uncertainty. Integration and reimbursement risks around the Personalis acquisition and NeXT Personal’s early commercial ramp, including only four MolDX coverage decisions and no disclosed commercial payer contracts, suggest that revenue conversion and margin durability may remain weak.